Abstract
Interactions between proteins of the Bcl-2 family play an important role in the regulation of apoptosis. Anti-apoptotic family members can heterodimerize with pro-apoptotic family members and antagonize their function, thus protecting against death. In cells protected from death by overexpression of Bcl-2 much of the Bax is present in Bax/Bcl-2 hetero-multimers and its death signal is blocked as it cannot homodimerize. This led us to use the Bcl-2/Bax heterodimer as a target for new compounds which may provide a therapy particularly suited to tumour cells for which resistance to conventional therapy is associated with elevated expression of Bcl-2. We assessed whether apoptosis could be induced in prostate tumour cells by blocking this heterodimerization with synthetic peptide sequences derived from the BH3 domain of pro-apoptotic Bcl-2 family members. Prostate cells were found to undergo up to 40% apoptosis 48 h following the introduction of synthetic peptides from the BH3 domains of Bax and Bak. The caspase inhibitor z-VAD.fmk provided protection against apoptosis mediated by these peptides. Immunoprecipitation studies revealed that introduction of peptides derived from the BH3 regions of Bak and Bax into cells blocked Bak/Bcl-2 heterodimerization. These data suggest that by blocking the dimerization through which Bcl-2 would normally inhibit apoptosis the apoptotic pathway driven by Bak was re-opened. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adams JM and Cory S (1998) The Bcl-2 protein family: Arbiters of cell survival. Science 281: 1322–1326
Allen RT, Cluck MW and Agrawal DK (1998) Mechanisms controlling cellular suicide: role of Bcl-2 and caspases. Cell Mol Life Sci 54: 427–445
Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S and Gellmann EP (1995) Androgens induce resistance to Bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 55: 735–738
Chittenden T, Flemmington C, Houghton AB, Ebb RG, Gallo GL, Elangovan B, Chinnadurai G and Lutz RJ (1995) A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding function. EMBO J 14: 5589–5596
Colombel M, Symmans F, Gil S, O’Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S and Buttyan R (1993) Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am J Pathol 143: 390–400
Diaz JL, Oltersdorf T, Horne W, McConnell M, Wilson G, Weeks S, Garcia T and Fritz CF (1997) A common binding site mediates heterodimerization and homodimerization of Bcl-2 family members. J Biol Chem 272, 17 11350–11355
Haldar S, Chintapalli J and Croce CM (1996) Taxol induces Bcl-2 phosphorylation and death in prostate cancer cells. Cancer Res 56: 1253–1255
Han JP, Sabbatini P, Perez D, Rao L, Modha D and White E (1996) The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev 10: 461–477
Hirotani M, Zhang Y, Fujita N, Naito M and Tsuruo T (1999) NH2-terminal BH4 domain of Bcl-2 is functional for heterodimerization with Bax and inhibition of apoptosis. J Biol Chem 274: 20415–20420
Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D and Reed JC (1998) Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 95: 4997–5002
Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S and Reed JC (1996) Immunohistochemical analysis of bcl-2, bax, bcl-xL, and mcl-1 expression on prostate cancers. Am J Pathol 148: 1567–1576
Kreis W (1995) Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer. Cancer Invest 13: 296–312
Kroemer G (1997) The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 3(6): 614–620
Mackey TJ, Borkowski A, Amin P, Jacobs SC and Kyprianou N (1998) bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 52(65): 1085–1090
McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM and Campbell ML (1992) Expression of the proto-oncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940–6944
Mundle SD, Gregory SA, Preislert HD and Raza A (1996) Enzymatic programming of apoptotic cell death. Pathiobiol 64: 161–170
Oltvai ZN, Milliman CL and Korsmeyer SJ (1993) Bcl-2 heterodimerizes in-vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609–619
Orth K and Dixit VM (1997) Bik and Bak induce apoptosis downstream of CrmA but upstream of inhibitor of apoptosis. J Biol Chem 272: 8841–8844
Otter I, Conus S, Ravn U, Rager M, Olivier R, Monney L, Fabbro D and Borner C (1998) The binding properties and biological activities of Bcl-2 and Bax in cells exposed to apoptotic stimuli. J Biol Chem 273: 6110–6120
Pan G, O’Rourke K and Dixit VM (1998) Caspase-9, Bcl-XL, and Apaf-1 form a terniary complex. J Biol Chem 273: 5841–5845
Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA and Cohen MB (1997) Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 57: 1758–1768
Tang DG and Porter AT (1997) Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 32: 284–293
Yang E and Korsmeyer SJ (1996) Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood 88: 386–401
Yang E, Zha J, Jockel J, Boise LH, Thompson CB and Korsmeyer SJ (1995) Bad, a heterodimeric partner for Bcl-x Land Bcl-2, displaces Bax and promotes cell death. Cell 80: 285–291
Yin XM, Oltvai ZN and Korsmeyer SJ (1994) BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369: 321–323
Zha H, Aime-Sempe C, Sato T and Reed JC (1996) Proapoptotic protein Bax heterodimerises with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J Biol Chem 271: 7440–7444
Zhou XM, Liu Y, Payne G, Lutz RJ and Chittenden T (2000) Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155. J Biol Chem 275: 25046–25051
Zhu W, Cowie A, Wasfy GW, Penn LZ, Leber B and Andrews DW (1996) Bcl-2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types. EMBO J 15: 4130–4141
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Finnegan, N., Curtin, J., Prevost, G. et al. Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions. Br J Cancer 85, 115–121 (2001). https://doi.org/10.1054/bjoc.2001.1850
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.1850
Keywords
This article is cited by
-
Formulation, evaluation and bioactive potential of Xylaria primorskensis terpenoid nanoparticles from its major compound xylaranic acid
Scientific Reports (2018)
-
A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells
Annals of Hematology (2007)
-
LIGHT sensitizes IFNγ–mediated apoptosis of HT-29 human carcinoma cells through both death receptor and mitochondria pathways
Cell Research (2004)
-
Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer
Pathology & Oncology Research (2004)
-
Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family
Leukemia (2003)
